Description
This compound is a derivative of methyl caffeate, a hydroxycinnamic acid; it exhibits chemopreventive potential, inhibiting the development of colon tumors in vivo.
| Product Unit Size | Cost | Quantity | Stock |
|---|
This compound is a derivative of methyl caffeate, a hydroxycinnamic acid; it exhibits chemopreventive potential, inhibiting the development of colon tumors in vivo.
| Purity | ≥98% |
|---|---|
| Formula | C18H18O4 |
| Formula Wt. | 298.33 |
| IUPAC Name | 2-phenylethyl 3-(3-hydroxy-4-methoxyphenyl)propanoate |
| Appearance | White Crystal Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Pereira MA. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs. Adv Exp Med Biol. 1999;470:55-63. PMID: 10709674.
SIRT2 inhibitor.
Synthetic peptide, vasopressin derivative; V2 a...
Macrolide antibiotic; peptidyl transferase inhi...
Polyphenol found in Camilla sinensis; HIV integ...
ALK and IGF-1R inhibitor.
2-methyl-1,4-naphthoquinone derivative
Inhibitor of ALK2, ALK3, ALK6, and AMPK.
Triterpenoid
Indoleamine 2,3-dioxygenase inhibitor.
SIRT inhibitor.
Non-depolarizing NMJ blocker; nAChR and M2/3 mA...
Bisaniline pyrimidine; pan-kinase inhibitor.
p53 inhibitor
RARα/β agonist.
FGFR inhibitor.
Histone H2-derived antimicrobial peptide found ...
EGFR inhibitor.
p110α and p110γ PI3K inhibitor.
Catechol-type flavonoid.
GHS-R1a agonist, γ-secretase inhibitor.